Entire-body PET Scans for Multiple Sclerosis
Exploratory Study of Entire-body PET Scans for Multiple Sclerosis
What it found
No result yet.
What was tested
Treatment tested
- Entire-body PET-CT scans
- Amyvid radiopharmaceutical
What it measured
Main measures
Entire-body PET imaging of demyelination of peripheral and central nervous system
During 1 day single PET-CT scan
Psychometric questionnaire for monitoring psychological health
Up to 90 days
Who could take part
MS (type not specified) · 25 to 55
Show the full criteria
Inclusion criteria
* Multiple sclerosis (MS) patients diagnosed by a credentialed neurologist experienced with care of multiple sclerosis patients. * Normal healthy subjects. * Willing and able to lie motionless on the PET-CT scanner bed for at least 10 minutes and up to 20 minutes for the duration of the PET-CT medical imaging scan.
Exclusion criteria
* Any additional complicating medical illness other than MS including any other neuropsychiatric illness unrelated to MS diagnosed prior to the onset of initial symptoms of MS. * Pregnancy or breast feeding. * Diabetes or other metabolic-endocrine disorders. * Any known concomitant acute infection. * History of metastatic or locally invasive cancer. * Recent surgery, chemotherapy or radiation therapy.
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.
Papers
Loading reviews and guidelines…
History
Started
Sept 2024
Main results due
Dec 2027
Finished
Jun 2028